Informed by the findings from prospective observational studies and randomized outcome trials, guidelines for the management of hypertension acknowledge that the benefit of treatment can be attributed largely to blood pressure (BP) reduction. Therefore, quantification of differential BP lowering of different agents within classes of anti-hypertensives is of practical importance. The objective of this analysis was to compare the efficacy of candesartan and losartan with respect to reduction in systolic and diastolic BP (SBP and DBP). A systematic literature search of databases from 1980 to 1 October 2008 identified 13 studies in which candesartan and losartan were compared in randomized trials in hypertensive patients. Data from 4066 patients were included in the analysis using a random effect model. Mean changes in SBP and DBP were compared for each drug alone and after stratification for dose and for combination with hydrochlorothiazide (HCTZ). On the basis of all the data, the weighted mean difference favoured candesartan-3.22 mm Hg (95% confidence interval (CI) 2.16, 4.29) for SBP and 2.21 mm Hg (95% CI 1.34, 3.07) for DBP. These findings were consistent when analyses according to dose and combination with HCTZ were carried out. Thus, it can be concluded that at currently recommended doses, candesartan is more effective than losartan in lowering BP.
Introduction
Placebo-controlled trials in mild-moderate hypertension and meta-analyses arising from these trials clearly established the benefits of treating hypertension to reduce cardiovascular (CV) events. 1 The most recent analysis from the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) has confirmed that all commonly used blood pressure (BP)-lowering treatments reduce the risk of major CV events, and that larger reductions in BP produce larger reductions in CV risk. 2 However, data from national surveys and other sources suggest a high prevalence of uncontrolled hypertension, with up to two-thirds of individuals with hypertension being inadequately treated. 3 All current hypertension treatment guidelines agree that the major benefit of treatment is associated with improved BP control. The European guidelines (ESH/ESC, 2007) suggest that all five major classes of anti-hypertensive agents are suitable for the initiation and maintenance of antihypertensive treatment, and furthermore suggest that, because many patients require more than one drug, emphasis on identification of the first class of drugs to be used is often futile. 4 This advice fails to acknowledge the fact that there may be significant differences in the magnitude of the anti-hypertensive responses between drugs within a given class.
Losartan was the first angiotensin II receptor blocker (ARB) to be approved for clinical use, and a number of other ARBs have subsequently been licensed for the treatment of hypertension. It has been suggested that all ARBs lower BP to a similar extent when administered at the usual recommended doses for the treatment of hypertension, and in addition that, at these recommended doses, the dose response for BP reduction with all ARBs is relatively flat. 5 This position was challenged by an analysis of the dose-response relationships for various ARBs, which showed a significant differentiation in the achieved BP reductions. 6 However, both analyses were potentially compromised, because only data from disparate studies submitted to the Food and Drug administration (FDA) for regulatory and licensing purposes were considered.
The ARBs have potentially important differences in pharmacokinetic and pharmacodynamic characteristics. For instance, losartan and candesartan cilexetil are both pro-drugs, but while losartan requires cytochrome P450-mediated biotransformation to yield the active moiety EXP-3174, 7 candesartan cilexetil is rapidly converted to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. 8 In vitro studies have shown that candesartan acts as an insurmountable antagonist and is able to virtually eliminate the AT 1 receptor-mediated effects of angiotensin II. 9 Compared with other widely used ARBs, candesartan shows high binding affinity for the AT 1 receptor, 9 that is, B80-fold higher than losartan and 10-fold higher than EXP 3174. Insurmountable antagonism provides long-lasting suppression of the reninangiotensin-aldosterone system, and it is suggested that this accounts for the magnitude of the antihypertensive efficacy of candesartan and for its sustained duration of effect. 10 To determine whether the pharmacological characteristics of candesartan offer advantages over the first in class ARB, losartan, with respect to antihypertensive efficacy, we undertook a meta-analysis of all studies in which the two agents were compared directly in hypertensive patients.
Methods

Search criteria
The aim was to identify all randomized controlled trials in which the anti-hypertensive effects of candesartan were compared with those of losartan in hypertensive patients. The search strategy was focused on the reports of clinical trials of candesartan versus losartan, which were identified through a systematic search of PubMed (from 1966 to 1 October 2008), Embase (from 1980 to 1 October 2008) and the Cochrane library (from 1 October 2008 onwards). The search combined terms related to candesartan and losartan (including MeSH search using exp 'benzimidazoles', exp 'tetrazoles' and exp 'benzoates', and keyword search using words 'candesartan', 'Blopress', 'Amias', 'Kenzen', 'Atacand', 'Ratacand', 'losartan', 'Cozaar', 'Hyzaar').
We also searched the reference lists of original reports and meta-analyses of studies involving ARBs (retrieved through the electronic searches) to identify studies that were not yet included in the computerized databases.
Trial eligibility
For a trial to be eligible for inclusion in the metaanalysis, it was required to meet a number of selection criteria, including (i) randomized clinical trials, including quasi-randomized clinical trials; (ii) patients with hypertension, with or without the simultaneous presence of other diseases such as metabolic syndrome and chronic kidney disease; (iii) intervention-candesartan versus losartanused as monotherapy or in fixed combination with hydrochlorothiazide (HCTZ); and (iv) BP reported at baseline and at end point or intermediate end point. In some instances, the publications involved the same group or subgroup of patients. To avoid duplication, only data from the most recent series were included in the analysis.
Statistical analysis
The outcome measure was assessed on an intention to treat basis, with the intention to treat population comprising all randomized patients who received study medication and in whom a valid baseline measurement was available.
Weighted 0.5 . The statistical analysis was performed using RevMan software version 5, provided by the Cochrane Information Management System, 11 using the methodology described by DerSimonian and Laird. 12 Given the disparate sample sizes and clinical characteristics among the study groups, an assumption that heterogeneity could be present even when no statistical significance was identified was made, and thus, a random effects model with inverse variance was fitted to the data. The results are reported with 95% confidence intervals (CIs). The w 2 -test was applied to all the comparisons to evaluate the evidence of heterogeneity of treatment effects between studies and a Z-test was performed to test the overall effect.
To evaluate the impact of potential methodological differences of various randomized clinical trials on the results of this meta-analysis, a sensitivity analysis was performed.
Results
The initial search process identified 48 studies that could potentially have been included in the analysis, and of these, a total of 13 randomized controlled trials met the pre-specified criteria for inclusion in this meta-analysis. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] A total of 4066 patients were included in the analysis, and the design and patient characteristics of randomized clinical trials included in the meta-analysis are shown in Table 1 . The majority of the trials had a randomized, doubleblind, parallel group design. In two of the trials, 13, 19 two doses of candesartan were compared with a single dose of losartan. In these two trials, the comparison of the two drugs was treated as independent evaluations.
The initial analysis focused on the comparison of candesartan and losartan in all the trials identified, including those employing a fixed-dose combination of the two drugs with HCTZ. There was a significantly greater reduction in SBP with the use of candesartan when compared with losartan (13 trials, 4066 patients) with a WMD in SBP of 3.22 mm Hg (95% CI 2.16, 4.29; Po0.001) (Figure 1 ). On the basis of the w 2 -test, there was no evidence of statistically significant heterogeneity in the trials included in the analysis (Figure 1) .
Despite the lack of evidence of statistical heterogeneity, because the doses of drug used in different trials included in the analysis are disparate, further analyses were performed on the basis of subdivision by dose. These were classified by use of monotherapy: 'low-dose' (4 and 8 mg candesartan and 25 and 50 mg losartan); 'high-dose' (12, 16 and 32 mg candesartan and 100 mg losartan); and combination with HCTZ. The results of these analyses are shown in Figures 2-5. All these analyses were consistent and showed statistically superior SBP reductions with candesartan when compared with losartan, and with no evidence of heterogeneity in the analyses. Analysis of the DBP data from the trials produced results that were compatible with those for SBP ( Table 2 ). Significant BP differentials favouring candesartan were noted for all the trials with WMD in DBP of 2.21 mm Hg (95% CI 1.34, 3.07) and a Z-value ¼ 4.99 (Po0.00001) ( Table 2) . Similar statistically significant differences in DBP were apparent for the subgroup analyses of monotherapy, 'low-dose', 'high-dose' and combination therapy with HCTZ (Table 2 ). However, with the DBP analyses, statistically significant heterogeneity was detected for a number of the analyses.
Sensitivity analyses were undertaken to evaluate the effect of individual trials on the overall findings for SBP and DBP. Sequential removal of individual trials did not significantly modify the overall findings.
Discussion
The results of the meta-analysis of data derived from 13 randomized clinical trials reveal that candesartan treatment produces a greater reduction in SBP and DBP when compared with treatment with losartan at the currently recommended doses. This differential was apparent even when the database was divided on the basis of the administered dose. These findings are consistent with an earlier analysis that suggested that there was a significant differentiation in the achieved BP reductions with various ARBs, with candesartan producing greater BP reductions over the full therapeutic dose-response relationship when compared with losartan and valsartan. 6 These findings are contrary to the suggestion that all ARBs lower BP to a similar extent when administered at their usual recommended doses for the treatment of hypertension. Gradman et al 1999
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Test for overall effect: Z = 5.86 (P < 0.00001) Figure 2 Comparison of the effects of candesartan and losartan on reduction in systolic blood pressure-monotherapy trials. Figure 3 Comparison of the effects of candesartan and losartan on reduction in systolic blood pressure-'low-dose' trials.
Weight
Study or Subgroup
Comparison of the anti-hypertensive effects of candesartan and losartan PA Meredith et al outcome trials indicate that the relative risk of CV events is related to BP levels in a continuous and linear manner. 26 Thus, there is a sound rationale for suggesting that when all other factors are equal, it is logical, when initiating anti-hypertensive treatment, to use within any given drug class, the agent most likely to produce the greatest BP reduction. It could be argued that small differences in BP reduction in individual patients are of little consequence, and a recent meta-analysis has suggested that differences in efficacy between drugs within a class are likely to be 'small and clinically unimportant'. 27 However, there is compelling evidence on a population basis that this is not the case. A meta-analysis of 61 cohort studies, supported by a meta-analysis of 147 randomized trials, 27, 28 suggests that when a single BP-lowering drug at a standard dose reduces DBP by B5 mm Hg, there is a resulting reduction of B25% in risk of coronary heart disease events (relative risk 0.75) and of B35% in stroke (relative risk 0.65), at the age 65 years. The results of our analyses suggest that candesartan monotherapy could increase the DBP reduction by an additional 1.8 mm Hg when compared with losartan. Adopting the previously published methodology, 29 it can be shown that this additional BP response could reduce coronary heart disease events by 32% (because 0.75 6.8/5 ¼ 0.68), an additional 7% points, and reduce stroke by 44% (0.65 6.8/5 ¼ 0.56), an additional 9% points. On the basis of the differential in DBP with the combination therapy using HCTZ (4.3 mm Hg), similar considerations predict that coronary heart disease events would be reduced by 41% and stroke by 55%.
Despite the BP differentials, it could be argued that there is no data from randomized outcome trials that support the contention that there are meaningful differences between the drugs. The LIFE (Losartan Intervention For Endpoint reduction in Figure 4 Comparison of the effects of candesartan and losartan on reduction in systolic blood pressure-'high-dose' trials. Figure 5 Comparison of the effects of candesartan and losartan on reduction in systolic blood pressure-'HCTZ combination' trials. Comparison of the anti-hypertensive effects of candesartan and losartan PA Meredith et al hypertension) trial 30 showed that with equal BP control, a losartan-based regimen was superior in reducing CV end points (mainly stroke) to an atenolol-based regimen in patients with left ventricular hypertrophy. Similar, but statistically nonsignificant, results were obtained in the SCOPE (Study On Cognition And Prognosis In The Elderly) study, 31 in which candesartan was compared with HCTZ in elderly patients. The apparent discrepancy between the studies is probably due to the inadequate statistical power of SCOPE, in which the protocol had to be changed during the course of the study for ethical reasons, and the disparate nature of the populations studied. Furthermore, a putative placebo comparison of the SCOPE and LIFE 32 suggested that there were no differences between the trials, and if anything, the outcomes in SCOPE were slightly better than those in LIFE. There are no outcome trials in which losartan and candesartan have been directly compared. However, the 'Real Life' study 33 has recently compared the two agents in a cohort study, conducted in selected primary care centres in Sweden. Candesartan was associated with a lower risk of CV disease, heart failure and peripheral artery disease compared with losartan, with no evidence of a differential BP reduction between the treatment groups.
The results obtained from our meta-analysis are subject to the limitations that are inherent in any meta-analysis, which are inevitably based on the pooling of data from disparate trials with different designs, different patient groups and of different duration, and excluding trials that have not been put into the public domain. Thus, some caution must be exercised in the interpretation of the resulting data. Nonetheless, this direct comparative analysis is more robust than the earlier indirect meta-analytical approaches that relied on the composite of individual placebo-controlled trials that had been submitted to the FDA for regulatory evaluation.
Given the consistency of the findings for both SBP and DBP and with different doses of the two drugs, there is compelling evidence to indicate that candesartan provides superior BP reductions when compared with losartan and is likely to be superior in CV protection.
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